Chemotherapy is one of the most important treatment modalities for advanced
hepatocellular carcinoma (HCC). On the basis of the results of two pivotal Phase III placebo …

Hepatocellular carcinoma is a common malignancy which usually emerges on a
background of chronic liver disease. Unfortunately, with contemporary management …

Background There are no systemic treatments for patients with hepatocellular carcinoma
(HCC) whose disease progresses during sorafenib treatment. We aimed to assess the …

Summary Background Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved
overall survival and progression-free survival compared with placebo in a randomised …

Background & Aims The RESORCE trial showed that regorafenib improves overall survival
(OS) in patients with hepatocellular carcinoma progressing during sorafenib treatment …

The hepatocellular carcinoma (HCC) treatment landscape changed a decade ago, with
sorafenib demonstrating survival benefit in the first-line setting and becoming the first …

Hepatocellular carcinoma (HCC) ranks number three among the most frequent causes of
death from solid tumors worldwide. With obesity and fatty liver diseases as risk factors on the …

Western and Eastern perspectives on therapeutic guidelines for hepatocellular carcinoma
(HCC) have many commonalities but may also differ in certain aspects, as described in this …

Cancer metabolism has been studied for years and adopted in the clinic for monitoring
disease progression and therapy response. Despite our growing knowledge of a distinctly …

BACKGROUND ADI‐PEG 20 is a pegylated form of the arginine‐depleting enzyme arginine
deiminase. Normal cells synthesize arginine with the enzyme argininosuccinate synthetase …